---
title: "Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289336856.md"
description: "A recent research study utilizing Nexalin's exclusive DIFS ™ 15 mA 77.5 Hz treatment system revealed significant and swift enhancements in anxiety and depression. These improvements were substantial in scale and were still noticeable during an 8-week check-up period following the treatment."
datetime: "2026-06-10T13:17:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289336856.md)
  - [en](https://longbridge.com/en/news/289336856.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289336856.md)
generator: "portal-rs"
---

# Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

A recent research study utilizing Nexalin's exclusive DIFS ™ 15 mA 77.5 Hz treatment system revealed significant and swift enhancements in anxiety and depression. These improvements were substantial in scale and were still noticeable during an 8-week check-up period following the treatment.

### Related Stocks

- [NXL.US](https://longbridge.com/en/quote/NXL.US.md)
- [NXLIW.US](https://longbridge.com/en/quote/NXLIW.US.md)

## Related News & Research

- [Nexalin Technology Announces $0.75M Direct Offering and $15M Equity Purchase Facility With Alumni Capital](https://longbridge.com/en/news/296538958.md)
- [Nexalin Technology prices registered direct offering of 2,419,355 shares at $0.31 each](https://longbridge.com/en/news/296538267.md)
- [Nexalin Technology Issues $1.17 Million OID Note for $1.0 Million Proceeds](https://longbridge.com/en/news/296654800.md)
- [Nexalin Technology enters USD 1.17 million unsecured note financing with institutional investor](https://longbridge.com/en/news/296654470.md)
- [EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life](https://longbridge.com/en/news/289332930.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**